Related Experiment Video
Updated: Jul 12, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Identification of VAYPQCV, a Gastrointestinally Stable Competitive DPP-IV Inhibitory Peptide from Bitter Leaf
Fitri Widya Handayani1,2,3, Christoper Caesar Yudho Sutopo4, Wei-Ting Hung5
1Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung, 91201, Taiwan.
Abstract:
Among hydrolysates generated from bitter leaf (Vernonia amygdalina) proteins using multiple proteases, the thermolysin-derived hydrolysate exhibited the strongest inhibition toward human dipeptidyl peptidase IV (DPP-IV). Bioassay-guided RP-HPLC fractionation coupled with LC-MS/MS analysis yielded five candidate peptides for synthesis and validation, among which the heptapeptide VAYPQCV (VV7) showed the strongest inhibitory activity with an IC50 of 19.8 ± 0.6 µM. Enzyme kinetic analysis demonstrated a classical competitive inhibition mode, with VV7 increasing the apparent Km without markedly affecting Vmax. Molecular docking further suggested that VV7 occupies the catalytic cavity of DPP-IV through interactions with Tyr666 in the S1 pocket and Glu205/Glu206 within the S2 subsite. VV7 also remained structurally intact after two-stage simulated gastrointestinal digestion, indicating resistance to extensive proteolytic degradation under the tested conditions. Collectively, these findings identify VV7 as a stable DPP-IV inhibitory peptide from bitter leaf and provide structural insight into its enzyme-level interaction with DPP-IV.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
The Physiology of Taste
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

